MX2017002897A - Forma de dosificación masticable semisólida para medicamentos de venta sin receta y método para producirlos. - Google Patents

Forma de dosificación masticable semisólida para medicamentos de venta sin receta y método para producirlos.

Info

Publication number
MX2017002897A
MX2017002897A MX2017002897A MX2017002897A MX2017002897A MX 2017002897 A MX2017002897 A MX 2017002897A MX 2017002897 A MX2017002897 A MX 2017002897A MX 2017002897 A MX2017002897 A MX 2017002897A MX 2017002897 A MX2017002897 A MX 2017002897A
Authority
MX
Mexico
Prior art keywords
semi
dosage form
chewable dosage
over
solid chewable
Prior art date
Application number
MX2017002897A
Other languages
English (en)
Inventor
T Westhusing Michael
Bai Yong
W Medri Mario
Original Assignee
Santa Cruz Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/626,897 external-priority patent/US20160067340A1/en
Application filed by Santa Cruz Pharmaceuticals Inc filed Critical Santa Cruz Pharmaceuticals Inc
Publication of MX2017002897A publication Critical patent/MX2017002897A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención proporciona una forma de dosificación masticable semisólida para usarse como un medicamento sin receta que contiene un ingrediente farmacéutico activo para tratar síntomas asociados con alergias, resfriados, tos, fiebre, dolor, trastornos gastrointestinales, sueño y otras condiciones comunes; la invención además proporciona una forma de dosificación masticable semisólida que contiene un ingrediente farmacéuticamente activo, un agente gelificante, gelatina, azúcar, un poliol y un agente de ajuste de pH; la invención también proporciona una forma de dosificación masticable semisólida que contiene un agente gelificante, azúcar, un poliol, glicerina y un agente de ajuste de pH.
MX2017002897A 2014-09-05 2015-09-08 Forma de dosificación masticable semisólida para medicamentos de venta sin receta y método para producirlos. MX2017002897A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462046712P 2014-09-05 2014-09-05
US201562115618P 2015-02-12 2015-02-12
US14/626,897 US20160067340A1 (en) 2014-09-05 2015-02-19 Semi-solid chewable dosage form for over-the-counter medications and method for producing same
PCT/US2015/049000 WO2016037189A1 (en) 2014-09-05 2015-09-08 Semi-solid chewable dosage form for over-the-counter medications and methods for producing same

Publications (1)

Publication Number Publication Date
MX2017002897A true MX2017002897A (es) 2018-01-11

Family

ID=55440441

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017002897A MX2017002897A (es) 2014-09-05 2015-09-08 Forma de dosificación masticable semisólida para medicamentos de venta sin receta y método para producirlos.

Country Status (5)

Country Link
EP (1) EP3188718A1 (es)
AU (1) AU2015311657A1 (es)
CA (1) CA2959800A1 (es)
MX (1) MX2017002897A (es)
WO (1) WO2016037189A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018237000A1 (en) * 2017-06-20 2018-12-27 Seattle Gummy Company PECTIN-BASED GEL COMPOSITION AND METHODS OF MAKING AND USING THE SAME
CN107334747A (zh) * 2017-07-25 2017-11-10 东莞云森生物医药科技有限公司 一种预防晕动症的口香糖
CN112822998A (zh) 2018-10-18 2021-05-18 强生消费者公司 新型剂型
CN109925289B (zh) * 2019-04-11 2021-05-25 海南普利制药股份有限公司 地氯雷他定分散片

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935243A (en) * 1988-12-19 1990-06-19 Pharmacaps, Inc. Chewable, edible soft gelatin capsule
WO2003090726A2 (en) * 2002-04-25 2003-11-06 Banner Pharmacaps, Inc. Chewable soft capsule
US20070292501A1 (en) * 2006-06-05 2007-12-20 Udell Ronald G Chewable soft gelatin capsules

Also Published As

Publication number Publication date
AU2015311657A1 (en) 2017-03-23
EP3188718A1 (en) 2017-07-12
CA2959800A1 (en) 2016-03-10
WO2016037189A1 (en) 2016-03-10

Similar Documents

Publication Publication Date Title
WO2017091749A8 (en) Shape changing drug delivery devices and methods
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
EA201401028A1 (ru) Фармацевтическая композиция, содержащая эмпаглифлозин и лекарственное средство от ожирения
JO3522B1 (ar) تركيب صيدلاني يتألف من كريات حمراء تغلف إنزيم يعتمد على بيريدكسال الفوسفات والعامل المساعد له
WO2015165413A8 (zh) 一种新型的稳定型抗体药物耦联物及其制备方法和用途
BR112015018168A2 (pt) inibidores de rock suaves
EA201591679A1 (ru) Способ нетоксического лечения абстиненции, вызванной лекарственным средством
MX366317B (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
MX2015009045A (es) Composiciones y metodos para tratar el dolor severo.
PH12016500863A1 (en) Tetracyclic autotaxin inhibitors
SG10201805267UA (en) Piperazine derivatives having multimodal activity against pain
MX2017002897A (es) Forma de dosificación masticable semisólida para medicamentos de venta sin receta y método para producirlos.
WO2014107730A3 (en) Use of fatty acid niacin conjugates for treating diseases
WO2014153385A3 (en) Methods of treating metabolic disorders
MX2016002408A (es) Metodos para el tratamiento de trastornos oticos pediatricos.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
DOP2015000071A (es) Fármaco combinado que comprende gemigliptina y metformina, y método para su preparación
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
EP3065737A4 (en) Oral pharmaceutical form for preventing vascular diseases, tablet as pharmaceutical form and gelatin capsule as pharmaceutical form
TR201902863T4 (tr) Eri̇tropoi̇eti̇n ve seftri̇akson i̇çeren farmasöti̇k bi̇r bi̇leşi̇m ve parki̇nson hastaliği demansinin tedavi̇si̇ i̇çi̇n bi̇r i̇lacin üreti̇lmesi̇nde bunun bi̇r kullanimi.
PH12020500472A1 (en) Autotaxin inhibitor compounds
UA84287U (ru) Способ коррекции метаболических нарушений у больных ветряной оспой
PL419074A1 (pl) Zastosowanie medyczne magnofloryny
Sangrador Pelluz Non-immediate hypersensitivity reaction, managed with desensitisation: case report
TH167893A (th) ยาสำหรับการรักษาผู้ป่วยที่มีอาการอื้อในหู